Cardiovascular effects after bolus application of cisatracurium. A comparison with vecuronium;Kardiovaskulare Effekte nach Bolusapplikation von Cisatracurium. Ein Vergleich mit Vecuronium

Anaesthesist

Volumn 45, Issue 11, 1996, Pages 1024-1029

  Soukup, J ^a,b   Doenicke, A ^b,d   Hoernecke, R ^b   Vorhammer, B ^b   Seebauer, A ^b   Moss, J ^c  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

cardiovascular effects; cisatracurium; muscle relaxant; stereoisomery

Indexed keywords

CISATRACURIUM; FENTANYL; ISOFLURANE; LORMETAZEPAM; NITROUS OXIDE; THIOPENTAL; VECURONIUM; ATRACURIUM; NEUROMUSCULAR BLOCKING AGENT;

ADULT; ANESTHESIA INDUCTION; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKING; RANDOMIZED CONTROLLED TRIAL; STEREOISOMERISM; ADOLESCENT; AGED; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; HEMODYNAMICS; MIDDLE AGED; PREMEDICATION;

ADOLESCENT; ADULT; AGED; ATRACURIUM; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PREMEDICATION; STEREOISOMERISM; VECURONIUM BROMIDE;

EID: 0029847655     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001010050335     Document Type: Article

References (25)

1. Belmont MR, Beemer G, Bownes P, Wastilla WB, Savarese J (1993) Comparative pharmacology of atracurium and one of its isomers, 51W89, in rhesus monkeys. Anesthesiology 79:S947
2. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ (1995) The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 82: 1139-1145
3. Booij LHDJ, Crul JF (1983) A comparison of vecuronium with the hypothetical ideal neuromuscular blocking drug. In: Agoston S et al. (eds) Clinical experiences with Norcuron, Excerpta Medica, Amsterdam, p 3
4. Doenicke A, Moss J, Lorenz W, Hoernecke R, Gottardis M (1994) Are hypotension and rash after atracurium really caused by histamine release? Anesth Analg 78: 967-972
5. Doenicke A, Soukup J, Hoernecke R, Moss J (1996) The lack of histamine release with cisatracurium: A double-blind comparison with recuroninus. Anaesth Analg 80: in press
6. Doenicke A, Moss J, Lorenz W, Mayer M, Rau J, Jedrzejewski A, Ostwald P (1996) Effect of oral anihistumine premedication on Mivacurium-induced histamine release and side effects. Br J Anaesth 77:421-423
7. Fastwood NB, Boyd AH, Parker CJR, Hunter JM (1995) Pharmakokinetic of 1R-cis1 'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth 75: 431-435
8. Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, Canfell C, Castagnoli K, Hennis PJ (1984) The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61: 699-702
9. Fahey MR, Rupp SM, Canfell C, Fisher DM, Miller RD, Sharma M, Castagnoli K, Hennis PJ (1995) Effect of renal failure on laudanosine excretion in man. Br J Anaesth 57: 1049-1051
10. Konstadt SN, Reich DL, Stanley III, De-Perio M, Chuey C, Schwartzbach C, Abou-Donia M (1995) A two-center comparisons the cardiovascular effects of cisatracurium (Nimbex) in patients with coronary artery disease. Anesth Analg 81: 1010-1014
11. Lepage JY, Malinovsky JM, Malinge M, Cozian A, Pinatid M (1993) 51W89: Dose-response, neuromuscular blocking profile and cardiovascular effects. Anesthesiology 79:A945
12. Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ (1995) The cardiovascular effects and histamin-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 82: 1131-1138
13. Lorenz W, Duda D, Dick W, Sitter H, Doenicke A, Black A, Weber D, Menke H, Stinner B, Junginger Th, Rothmund M, Ohmann C, Healy MJR (1994) Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Lancet 343: 933-940
14. Maehr RB, Wastilla WB (1993) Comparative pharmacology of atracurium and six isomers in cats. Anesthesiology 79: A950
15. Mellinghoff H, Pirpiri P, Buzello W (1994) Comparison of 51W89 and atracrium administered by continuous infusion. Anesth Analg 78:S283
16. Meretoja OA, Taivainen T, Wirtavuori K (1995) Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia. Br J Anaesth 74: 6-11
17. Ornstein E, Lien C, Matteo RS, Ostapkovich N, Wolf K, Kisor D, Diaz J (1994) Pharmacodynamics and pharmacokinetics of 51W89 in geriatric surgical patients. Anesthesiology 81:A1075
18. Savarese JJ, Kitz R (1975) Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology 42: 236-239
19. Stenlake JB, Waighl RB, Urwin J (1983) Atracurium: conception and inception. Br J Anaesth 55: 3-10
20. Stenlake JB, Waighl RD, Dewar GH (1984) Biodegredable neuromuscular blocking agents. VI. Stereochemical studies on atracurium and related polyalkylene di-esters. Eur J Mod Chem 19: 441-450
21. Stout RG, Belmont MR, Pavlin EG, Abalos A, Lien CA (1994) Evaluation of intubation at 90 and 120 seconds following 51W89 administration. Anesthesiology 81:A1078
22. Tsui D, Graham GG, Torda TA (1987) The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology 67: 722-728
23. Vlasselaers D, Mulier JP, Berg H, Hom A, Van Aken H (1994) Hemodynamic effects of a potent isomer of atracurium (51W89) in cardiac patients. Anesthesiology 81:A1079
24. Wastilla WB, Maehr RB, LaMunion GL, Belmont MR, Savarese JJ (1996) Preclinical pharmacology of cisatracurium besylate. Curr Opin Anaesth [Suppl 1] S: 2-8
25. Ward S, Boheimer N, Weatherly BC, Simmonds RJ, Dopson TA (1987) Pharmacokinetics of atracurium and its metabolites in patients with normal renal function and in patients with renal failure. Br J Anaesth 59: 697-706